- Conditions
- Cancer Survivor, Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- therapeutic testosterone, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 5,450
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor Cancer
- Interventions
- SB-485232
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Indianapolis, Indiana • Durham, North Carolina + 1 more
- Conditions
- Solid Tumors
- Interventions
- Peptides, Poly-ICLC, Lenalidomide
- Biological · Drug
- Lead sponsor
- Nina Bhardwaj
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neoplasm
- Interventions
- TRC102 + pemetrexed
- Drug
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Cleveland, Ohio
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, Metastatic Triple Negative Breast Cancer
- Interventions
- CTLA-4 Antibody, Hypofractionated Radiotherapy
- Drug · Radiation
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Solid Tumors, Adult
- Interventions
- HMPL-A251
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Plantation, Florida • Tamarac, Florida + 4 more
- Conditions
- Cancer
- Interventions
- aprepitant, dexamethasone, ondansetron, placebo
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Solid Tumors, Advanced Cancer
- Interventions
- AMG 531, Carboplatin, Adriamycin, Ifosfamide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy, Keratinocyte Growth Factor, Alemtuzumab, Thiotepa, Etoposide, Fludarabine, Melphalan, Tacrolimus, Cyclosporine A, Mycophenolate mofetil
- Procedure · Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Advanced Solid Tumors, Kidney Disease, Renal Impairment
- Interventions
- AMG 386 + Paclitaxel, AMG 386
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Lebanon, New Hampshire + 1 more
- Conditions
- Solid Tumors
- Interventions
- M3541, Palliative Radiotherapy (RT)
- Drug · Radiation
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • St Louis, Missouri • Hackensack, New Jersey + 2 more
- Conditions
- Refractory Cancer, Metastatic Cancer, Recurrent Cancer, Unresectable Carcinoma, Solid Tumor, Adult, Advanced Cancer, Advanced Solid Tumor
- Interventions
- SNK01, Avelumab, Pembrolizumab
- Biological · Drug
- Lead sponsor
- NKGen Biotech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
- Interventions
- INV-1120, Pembrolizumab
- Drug · Combination Product
- Lead sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Lafayette, Indiana • San Antonio, Texas
- Conditions
- Solid Tumors, Neoplasms
- Interventions
- Mocertatug rezetecan
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Santa Rosa, California + 14 more
- Conditions
- Advanced Solid Tumors
- Interventions
- VBC108
- Drug
- Lead sponsor
- VelaVigo Bio Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Duarte, California • Grand Rapids, Michigan • New York, New York + 2 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- therapeutic angiotensin-(1-7)
- Biological
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Neoplasms
- Interventions
- RG1507
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • New Brunswick, New Jersey • Houston, Texas
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Afatinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adult, Solid Tumor
- Interventions
- capecitabine, enzastaurin hydrochloride
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- levocarnitine, placebo
- Dietary Supplement · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 116
- States / cities
- Palo Alto, California • Stanford, California • Danbury, Connecticut + 85 more
- Conditions
- Lung Cancer Stage IV
- Interventions
- Blood and tumor tissue analysis, Clinical response.
- Other
- Lead sponsor
- Holy Cross Hospital, Maryland
- Other
- Eligibility
- 18 Years to 70 Years
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Solid Tumors
- Interventions
- RenovoCath®
- Device
- Lead sponsor
- RenovoRx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Coral Gables, Florida • Pittsburgh, Pennsylvania • Burlington, Vermont
- Conditions
- Lymphoma
- Interventions
- CUDC-427
- Drug
- Lead sponsor
- Curis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • San Antonio, Texas
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
- Interventions
- RNDO-564, Pembrolizumab
- Drug
- Lead sponsor
- Rondo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more